Novo Nordisk A/S : Data presented at ObesityWeek showed Saxenda® treatment demonstrated significant and sustained weight loss over three years compared with placebo

Read the full release with references in PDF

Los Angeles, US, 4 November 2015 - Today, new data from the phase 3a SCALE(TM) (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and Prediabetes three-year trial extension were presented at ObesityWeek 2015, the 3^rd annual combined congress of the American Society for Metabolic and Bariatric Surgery and The Obesity Society. The extension part of the trial (n=2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline), demonstrated that treatment with Saxenda^® (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity resulted in significant and sustained weight loss over the three-year span, compared with placebo (reduced-calorie diet and increased physical activity alone).1

^[i] le Roux C, Astrup A, Fujioka K, et al. Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial. ObesityWeek 2015.